Revusiran clinical trials
How each study uses revusiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses revusiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac AmyloidosisCompletedPhase 2Alnylam PharmaceuticalsNCT01981837Written as ALN-TTRSC (revusiran) for subcutaneous administration
- A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac AmyloidosisCompletedPhase 2Alnylam PharmaceuticalsNCT02292186Written as Revusiran (ALN-TTRSC)
- The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver TransplantCompletedPhase 2Alnylam PharmaceuticalsNCT02595983Written as Revusiran
- ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)CompletedPhase 3Alnylam PharmaceuticalsNCT02319005Written as Revusiran (ALN-TTRSC)
- A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy VolunteersCompletedPhase 1Alnylam PharmaceuticalsNCT01814839Written as ALN-TTRSC (revusiran)
Codes
What other systems call revusiran · ClinicalTrials.gg INT000607
- MeSH (NLM) C000614277revusiranOne source NLM
- UNII (FDA) ZE6EHM8Z3AREVUSIRANConfirmed FDA, NLM
- NCI Thesaurus C152204RevusiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000614277 | revusiran | One source NLM |
| UNII (FDA) | ZE6EHM8Z3A | REVUSIRAN | Confirmed FDA, NLM |
| NCI Thesaurus | C152204 | Revusiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.